Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6ZMR3
UPID:
LDH6A_HUMAN
Alternative names:
-
Alternative UPACC:
Q6ZMR3; D3DQY5
Background:
L-lactate dehydrogenase A-like 6A plays a pivotal role in cellular metabolism by catalyzing the interconversion of L-lactate and pyruvate, utilizing nicotinamide adenine dinucleotide (NAD+) as a coenzyme. This enzyme's activity is crucial for energy production in cells. Additionally, it has been found to significantly enhance the transcriptional activity of JUN when overexpressed, indicating its potential regulatory role in gene expression.
Therapeutic significance:
Understanding the role of L-lactate dehydrogenase A-like 6A could open doors to potential therapeutic strategies. Its involvement in key metabolic processes and gene regulation presents a unique opportunity for targeting metabolic disorders and diseases with a genetic basis.